These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9863218)

  • 21. [Evaluation of theophylline population pharmacokinetics in adult hospitalized patients using NONMEM analysis].
    Li Z; Chen G
    Zhongguo Yao Li Xue Bao; 1994 May; 15(3):267-70. PubMed ID: 7976385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amikacin population pharmacokinetics among paediatric burn patients.
    Sherwin CM; Wead S; Stockmann C; Healy D; Spigarelli MG; Neely A; Kagan R
    Burns; 2014 Mar; 40(2):311-8. PubMed ID: 23876785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics of amikacin in geriatric patients studied with the NPEM-2 algorithm.
    Debord J; Charmes JP; Marquet P; Merle L; Lachâtre G
    Int J Clin Pharmacol Ther; 1997 Jan; 35(1):24-7. PubMed ID: 9021438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity.
    Gálvez R; Luengo C; Cornejo R; Kosche J; Romero C; Tobar E; Illanes V; Llanos O; Castro J
    Int J Antimicrob Agents; 2011 Aug; 38(2):146-51. PubMed ID: 21612894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing.
    Xuan D; Nicolau DP; Nightingale CH
    Int J Antimicrob Agents; 2004 Mar; 23(3):291-5. PubMed ID: 15164971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Individual variability of pharmacokinetic parameters of amikacin in the elderly: retrospective studies].
    Vincent S; Maire PH; Bataillard T; Denjean E; Ducrozet P; Laffont A; Visent C; Jelliffe RW
    Pathol Biol (Paris); 1996 Sep; 44(7):667-74. PubMed ID: 8977923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.
    Variol P; Nguyen L; Tranchand B; Puozzo C
    Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative pharmacokinetics of amikacin in Greyhound and Beagle dogs.
    KuKanich B; Coetzee JF
    J Vet Pharmacol Ther; 2008 Apr; 31(2):102-7. PubMed ID: 18307501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
    Lee CK; Rowinsky EK; Li J; Giles F; Moore MJ; Hidalgo M; Capparelli E; Jolivet J; Baker SD
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2158-65. PubMed ID: 16609029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults.
    Tod M; Lortholary O; Seytre D; Semaoun R; Uzzan B; Guillevin L; Casassus P; Petitjean O
    Antimicrob Agents Chemother; 1998 Apr; 42(4):849-56. PubMed ID: 9559795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
    Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets.
    Goldstein I; Wallet F; Nicolas-Robin A; Ferrari F; Marquette CH; Rouby JJ
    Am J Respir Crit Care Med; 2002 Nov; 166(10):1375-81. PubMed ID: 12406838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
    van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implementation and evaluation of a once-daily amikacin dosing protocol in a long-term care facility.
    Yoshida M; Morita R; Lefor AT; Nabeshima T
    Int J Antimicrob Agents; 2007 Jan; 29(1):113-6. PubMed ID: 17137756
    [No Abstract]   [Full Text] [Related]  

  • 35. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetics of cefepime in neonates with severe nosocomial infections.
    Lima-Rogel V; Medina-Rojas EL; Del Carmen Milán-Segovia R; Noyola DE; Nieto-Aguirre K; López-Delarosa A; Romano-Moreno S
    J Clin Pharm Ther; 2008 Jun; 33(3):295-306. PubMed ID: 18452417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Experimental and clinical studies of intravenous infusion of amikacin in acute respiratory tract infections].
    Ito T
    Jpn J Antibiot; 1982 Aug; 35(8):2111-25. PubMed ID: 7154253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients.
    Li C; Kuti JL; Nightingale CH; Nicolau DP
    J Clin Pharmacol; 2006 Oct; 46(10):1171-8. PubMed ID: 16988206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetics of amikacin in critically ill patients.
    Bressolle F; Gouby A; Martinez JM; Joubert P; Saissi G; Guillaud R; Gomeni R
    Antimicrob Agents Chemother; 1996 Jul; 40(7):1682-9. PubMed ID: 8807062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of unilateral nephrectomy on the pharmacokinetics of amikacin in humans.
    Drozdzik M; Domanski L; Wojcicki J; Gawronska-Szklarz B; Machoy P; Pudlo A
    J Pharm Pharmacol; 2002 Apr; 54(4):509-14. PubMed ID: 11999128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.